Literature DB >> 12614536

Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects.

Roman Huber1, Reinhild Klein, Peter A Berg, Rainer Lüdtke, Michael Werner.   

Abstract

BACKGROUND AND OBJECTIVES: Mistletoe preparations, which are widely used among patients with cancer in Germany, have immunomodulating properties in vitro and in vivo. The aim of this evaluation was to determine and compare the effects of a lectin-rich (Iscador Qu [IQ] special, Weleda Company, Schwäbisch, Gmünd, Germany.) and a lectin-poor but viscotoxin-rich (Iscador Pini [IP] Weleda Company) mistletoe preparation on clinical and hematologic parameters in healthy subjects.
DESIGN: In a double-blinded study, 48 volunteers were randomized to one of three groups: 16 received IQ or IP in increasing doses or placebo twice per week subcutaneously for 12 weeks. The differential blood count and the acute phase markers haptoglobin and C-reactive protein were examined weekly and the symptoms were scored using standardized questionnaires.
RESULTS: IQ resulted in significant eosinophilia (315 +/- 109) beginning at week 5 (until week 12) compared to IP (183 +/- 120) or placebo (200 +/- 179). Furthermore, the acute phase marker haptoglobin was significantly increased in the IQ group during week 4. Dose-dependent local reactions (LRs) at the injection site occurred in all subjects who received mistletoe preparations but were stronger in the IQ-treated subjects than in the IP-treated group. The LRs observed in the IQ-treated group were characterized by stronger itching and longer latency than LRs in the IP-treated group (p < 0.05). Severe side-effects did not occur in any of the probands.
CONCLUSIONS: IQ but not IP can induce eosinophilia in healthy individuals, and this may be related to its content of mistletoe lectins. In contrast, exposure to the viscotoxin-enriched extract IP did not result in specific changes of hematologic parameters. Furthermore, intensity and time course of local reactions seemed to depend on the concentration of mistletoe lectins in those extracts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12614536     DOI: 10.1089/10755530260511847

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  5 in total

1.  Mistletoe as a treatment for cancer.

Authors:  Edzard Ernst
Journal:  BMJ       Date:  2006-12-23

Review 2.  Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.

Authors:  Gunver S Kienle; Renate Grugel; Helmut Kiene
Journal:  BMC Complement Altern Med       Date:  2011-08-28       Impact factor: 3.659

3.  Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects.

Authors:  Roman Huber; Holger Lüdtke; Johannes Wieber; Christiane Beckmann
Journal:  BMC Complement Altern Med       Date:  2011-11-24       Impact factor: 3.659

4.  Effect of gamma irradiation on mistletoe (Viscum album) lectin-mediated toxicity and immunomodulatory activity.

Authors:  Nak-Yun Sung; Eui-Baek Byun; Du-Sup Song; Yeung-Bae Jin; Jae-Kyung Kim; Jong-Heum Park; Beom-Seok Song; Pil-Mun Jung; Myung-Woo Byun; Ju-Woon Lee; Sang-Hyun Park; Jae-Hun Kim
Journal:  FEBS Open Bio       Date:  2013-01-22       Impact factor: 2.693

5.  Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials?

Authors:  Renatus Ziegler
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-04       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.